REG - Ilika plc - Ilika Secures Stereax Electrode Order from Cirtec

IlikaAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260121:nRSU6529Pa&default-theme=true

RNS Number : 6529P  Ilika plc  21 January 2026

21 January 2026

Ilika plc

('Ilika,' the 'Company,' or the 'Group')

 

Ilika Secures First Stereax Electrode Order from Cirtec

 

Strategic Partnership Advances to Revenue Generation Phase

 

Ilika (AIM: IKA), the UK pioneer in solid state battery technology, has
secured its first revenue-generating purchase order from Cirtec Medical
(Cirtec) for the supply of Stereax electrodes, marking the commercial
transition of this strategic partnership. This milestone order for the
critical conductive elements that enable battery functionality follows two
years of development work and successful prototype delivery in December 2025.

 

The Stereax electrodes will support the ramp up of Stereax M300 production at
Cirtec, targeting a wide range of applications across active implantable
medical devices (AIMDs), including powering implanted sensors,
neurostimulators, orthopaedic implants, orthodontic wearables and
ophthalmology devices. This purchase represents Ilika's entry into the
commercial phase of its medical device battery technology.

 

In August 2023, Ilika announced an agreement whereby the Company would retain
specific battery manufacturing processes at its UK facility as a service to
Cirtec. After successfully delivering early versions of Stereax M300 batteries
in December 2025 (with primary manufacturing occurring at Cirtec's
Massachusetts facility), this relationship has now progressed to commercial
orders, with Cirtec purchasing production quantities of electrodes from Ilika.
The Stereax M300 batteries are currently being evaluated by 21 customers for
their applications.

 

Shawn Martin, Vice President at Cirtec Medical, said: "This marks an important
transition from the earlier stages of technology transfer to commercial
production coordinated from our facility here in the USA."

 

Graeme Purdy, CEO of Ilika, said: "The receipt of this first commercial
electrode order validates the strong market momentum building behind our
Stereax technology and demonstrates the successful execution of our production
strategy. This revenue-generating phase of our partnership with Cirtec
positions us to support their manufacturing scale-up while accelerating
product integration across numerous high-value medical device applications."

 

The companies will showcase their partnership at upcoming industry events,
with Ilika supporting Cirtec at the North America Neuromodulation Society
(NANS) annual meeting in Las Vegas on January 23-24, 2026. Additionally,
Cirtec will exhibit and represent Stereax technology at MD&M West in
Anaheim on February 3-5, 2026, further highlighting the commercial readiness
of this innovative battery solution.

 

The information communicated within this announcement is deemed to constitute
inside information as stipulated under the Market Abuse Regulations (EU) No.
596/2014 which is part of UK law by virtue of the European Union (withdrawal)
Act 2018. Upon the publication of this announcement, this inside information
is now considered to be in the public domain.

 

ENDS--

 

Enquiries:

 

 Ilika Plc                                             www.ilika.com (http://www.ilika.com/)
 Graeme Purdy, Chief Executive

                                                     Via FTI Consulting
 Jason Stewart, Chief Financial Officer

 Cavendish Capital Markets Limited (Nomad and Broker)  +44 (0)131 220 9772
 Peter Lynch

                                                     +44 (0)131 220 9771
 Neil McDonald

 FTI Consulting (Comms Advisors)                       ilika@fticonsulting.com

 Ben Brewerton

 Elizabeth Adams

 Dwight Burden

 

About Ilika plc

 

Ilika is a global expert in the development of solid-state battery technology
for electric vehicles, medical devices and consumer appliances. The Company's
pioneering next-generation technologies aim to provide scalable, affordable
alternatives to conventional batteries, to industries which need to
incorporate a smaller, lighter, and safer power source in their products.

 

The Company has two product lines. Its Stereax batteries are designed for
powering miniature medical implants, industrial wireless sensors and Internet
of Things (IoT) applications and the Goliath large format batteries are
designed for EV cars and cordless appliances.

 

Through its licensing business model, Ilika supplies its IP portfolio to both
OEMs and manufacturing partners in exchange for a license fee and future
royalties.

 

About Cirtec Medical‍

 

Cirtec Medical is a global leader in design, development, and manufacturing of
complex Class II and III medical devices, specializing inactive implant
systems, interventional devices, precision components, and thin film and
microelectronics. Since 1987, Cirtec Medical has built extensive in-house
capabilities that enable the company to serve as a single-source partner and
collaborate with customers to transform their technology into innovative
medical devices across a wide array of therapies, including cardiology,
neurology, orthopedics and other minimally invasive device applications.
Cirtec Medical's deep expertise in precision component design and
manufacturing supports every stage of the product lifecycle, ensuring
uncompromising quality and performance. With 11 global facilities and a
vertically integrated approach, Cirtec Medical aims to expedite time to
market, reduce risk, and accelerate revenue generation for our partners. Learn
more at CirtecMed.com.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCPPUUCGUPQGQU



            Copyright 2019 Regulatory News Service, all rights reserved